146 related articles for article (PubMed ID: 21736504)
1. Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma.
Lamm W; Vogl UM; Bojic M; Zielinski C; Klingler C; Kramer G; Schmidinger M
Acta Oncol; 2012 Jan; 51(1):101-6. PubMed ID: 21736504
[TBL] [Abstract][Full Text] [Related]
2. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
Hudes G; Carducci M; Tomczak P; Dutcher J; Figlin R; Kapoor A; Staroslawska E; Sosman J; McDermott D; Bodrogi I; Kovacevic Z; Lesovoy V; Schmidt-Wolf IG; Barbarash O; Gokmen E; O'Toole T; Lustgarten S; Moore L; Motzer RJ;
N Engl J Med; 2007 May; 356(22):2271-81. PubMed ID: 17538086
[TBL] [Abstract][Full Text] [Related]
3. Temsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral center.
Afshar M; Pascoe J; Whitmarsh S; James N; Porfiri E
Drug Des Devel Ther; 2015; 9():13-9. PubMed ID: 25552898
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
Motzer RJ; Hudes GR; Curti BD; McDermott DF; Escudier BJ; Negrier S; Duclos B; Moore L; O'Toole T; Boni JP; Dutcher JP
J Clin Oncol; 2007 Sep; 25(25):3958-64. PubMed ID: 17761980
[TBL] [Abstract][Full Text] [Related]
5. Temsirolimus in renal cell carcinoma.
Otto T; Eimer C; Gerullis H
Transplant Proc; 2008 Dec; 40(10 Suppl):S36-9. PubMed ID: 19100905
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.
Chan S; Scheulen ME; Johnston S; Mross K; Cardoso F; Dittrich C; Eiermann W; Hess D; Morant R; Semiglazov V; Borner M; Salzberg M; Ostapenko V; Illiger HJ; Behringer D; Bardy-Bouxin N; Boni J; Kong S; Cincotta M; Moore L
J Clin Oncol; 2005 Aug; 23(23):5314-22. PubMed ID: 15955899
[TBL] [Abstract][Full Text] [Related]
7. A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors.
Fujisaka Y; Yamada Y; Yamamoto N; Horiike A; Tamura T
Jpn J Clin Oncol; 2010 Aug; 40(8):732-8. PubMed ID: 20430774
[TBL] [Abstract][Full Text] [Related]
8. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.
Hudes GR; Berkenblit A; Feingold J; Atkins MB; Rini BI; Dutcher J
Semin Oncol; 2009 Dec; 36 Suppl 3():S26-36. PubMed ID: 19963097
[TBL] [Abstract][Full Text] [Related]
9. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
Malizzia LJ; Hsu A
Clin J Oncol Nurs; 2008 Aug; 12(4):639-46. PubMed ID: 18676330
[TBL] [Abstract][Full Text] [Related]
10. Temsirolimus in daily use: results of a prospective multicentre noninterventional study of patients with metastatic kidney cancer.
Schrader AJ; Seseke S; Keil C; Herrmann E; Goebell PJ; Weikert S; Steffens S; Bergmann L; Roigas J; Steiner T
Eur Urol; 2014 Aug; 66(2):275-81. PubMed ID: 24012472
[TBL] [Abstract][Full Text] [Related]
11. Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus.
Lee CK; Marschner IC; Simes RJ; Voysey M; Egleston B; Hudes G; de Souza P
Clin Cancer Res; 2012 Jun; 18(11):3188-96. PubMed ID: 22472176
[TBL] [Abstract][Full Text] [Related]
12. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.
Grünwald V; Karakiewicz PI; Bavbek SE; Miller K; Machiels JP; Lee SH; Larkin J; Bono P; Rha SY; Castellano D; Blank CU; Knox JJ; Hawkins R; Anak O; Rosamilia M; Booth J; Pirotta N; Bodrogi I;
Eur J Cancer; 2012 Feb; 48(3):324-32. PubMed ID: 21803569
[TBL] [Abstract][Full Text] [Related]
13. Tumour flare during interruption of temsirolimus treatment for metastatic renal cell cancer.
Paterson C; Jones RJ
Clin Oncol (R Coll Radiol); 2009 Nov; 21(9):732-3. PubMed ID: 19665360
[No Abstract] [Full Text] [Related]
14. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
Mancuso A; Di Paola ED; Leone A; Catalano A; Calabrò F; Cerbone L; Zivi A; Messina C; Alonso S; Vigna L; Caristo R; Sternberg CN
BJU Int; 2012 Jan; 109(2):200-6. PubMed ID: 22212284
[TBL] [Abstract][Full Text] [Related]
15. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study.
Calvo E; Escudier B; Motzer RJ; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Ravaud A; Kim D; Panneerselvam A; Anak O; Figlin RA
Eur J Cancer; 2012 Feb; 48(3):333-9. PubMed ID: 22209391
[TBL] [Abstract][Full Text] [Related]
16. Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany.
Gerullis H; Bergmann L; Maute L; Eimer C; Otto T
Cancer Chemother Pharmacol; 2009 May; 63(6):1097-102. PubMed ID: 18818922
[TBL] [Abstract][Full Text] [Related]
17. Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies.
Patel SB; Stenehjem DD; Gill DM; Tantravahi SK; Agarwal AM; Hsu J; Vuong W; Pal SK; Agarwal N
Clin Genitourin Cancer; 2016 Apr; 14(2):153-9. PubMed ID: 26781820
[TBL] [Abstract][Full Text] [Related]
18. Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma.
Naito S; Tsukamoto T; Murai M; Fukino K; Akaza H
BJU Int; 2011 Dec; 108(11):1813-9. PubMed ID: 21481133
[TBL] [Abstract][Full Text] [Related]
19. Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case series.
Lunardi G; Armirotti A; Nicodemo M; Cavallini L; Damonte G; Vannozzi MO; Venturini M
Clin Ther; 2009 Aug; 31(8):1812-9. PubMed ID: 19808140
[TBL] [Abstract][Full Text] [Related]
20. Temsirolimus: a safety and efficacy review.
Bukowski RM
Expert Opin Drug Saf; 2012 Sep; 11(5):861-79. PubMed ID: 22861825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
